A prospective randomised controlled trial assessing the efficacy of intravitreal bevacizumab in patients with minimally classic and occult choroidal neovascularisation secondary to age-related macular degeneration

Frimley Park Hospital NHS Trust (UK)0 个研究点目标入组 100 人开始时间: 2007年12月18日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Age >50 years
•2. Fluorescein angiographic evidence of minimally classic or occult choroidal neovascular membrane
•3. Best Corrected Visual Acuity (BCVA) 20/40 - 20/320
•4. BCVA in no study eye better than 20/320
•5. If both eyes are eligible then only the worst eye will be enrolled
•6. Willing to attend scheduled visits

•1. Medical conditions:
•1.1. Uncontrolled hypertension
•1.2. Patients on more than 3 antihypertensive medications
•1.3. Patients in whom a change in anti-hypertensive drug was initiated within 3 months preceding baseline visit.
•1.4. Previous thrombembolic phenomenon
•1.5. On Warfarin or anticoagulants
•1.6. Recent Myocardial Infarction (MI)
•1.7. Recent major surgery (within 28 days)
•2. Ocular conditions:
•3. Glaucoma (IntraOcular Pressure [IOP] >25, on anti-glaucoma treatment, glaucoma surgery)
•4. Active intraocular or extraocular inflammation
•5. Retinal vascular disease
•6. Other sources of chorodal neovascular membrane
•7. Previous PhotoDynamic Therapy (PDT)
•8. Predominantly classic membranes
•9. Previous cataract surgery (within 6 months)
•10. Aphakia
•11. Other retinal conditions that may effect visual outcome
•3.1. Allergy to Fluorescein
•3.2. Inability to obtain colour photographs, fluorescein angiogram, Optical Coherence Tomography (OCT) images
•3.3. Allergy to anti Vascular Endothelial Growth Factor (VEGF) medications
•3.4. Allergy to humanised monoclonal antibody
•3.5. Inability to comply with follow-up procedures

发起方

Frimley Park Hospital NHS Trust (UK)